[Tyr0]-C-Type Natriuretic Peptide (32-53)

[Tyr0]-C-Type Natriuretic Peptide (32-53) is a synthetic peptide fragment derived from the C-terminal region of C-type natriuretic peptide (CNP), with an N-terminal tyrosine modification. As a member of the natriuretic peptide family, it is notable for its roles in vascular homeostasis, cell signaling, and peptide-receptor interaction studies. The addition of a tyrosine residue at the N-terminus enables advanced labeling strategies and enhances utility in receptor binding assays and biochemical investigations. Researchers employ this peptide to explore the structure-function relationships within the natriuretic peptide system, as well as to dissect the molecular mechanisms underlying natriuretic peptide signaling in both physiological and pathophysiological contexts.

Receptor binding studies: The modified peptide is widely used in binding assays to evaluate the interaction between natriuretic peptides and their cognate receptors, particularly natriuretic peptide receptor-B (NPR-B). Its defined sequence and N-terminal modification facilitate the analysis of ligand-receptor specificity, allowing researchers to dissect the contribution of particular amino acid residues to receptor affinity and signaling efficacy. Such studies are instrumental in elucidating the molecular determinants of CNP-mediated signal transduction in vascular, skeletal, and neural tissues.

Peptide structure-activity relationship analysis: Incorporation of an N-terminal tyrosine in [Tyr0]-C-Type Natriuretic Peptide (32-53) provides a unique tool for probing the structural features that govern biological activity within the natriuretic peptide family. By comparing the functional properties of this analog with those of native and other modified peptides, researchers can map critical domains necessary for receptor activation, peptide stability, and downstream signaling. These insights are essential for rational peptide design and the development of selective molecular probes.

Fluorescent and radiolabeling applications: The presence of a terminal tyrosine residue enables efficient labeling with radioisotopes such as iodine-125 or with fluorescent tags, supporting sensitive detection in biochemical assays. Such labeled peptides are valuable for investigating peptide distribution, receptor localization, and real-time tracking of ligand-receptor interactions in live-cell and tissue-based experiments. These applications are fundamental to advancing our understanding of peptide dynamics in complex biological systems.

Enzyme substrate studies: As a defined peptide substrate, [Tyr0]-CNP (32-53) is employed to assess the activity and specificity of proteases and peptidases involved in natriuretic peptide metabolism. By monitoring the cleavage patterns and degradation kinetics of the peptide in the presence of candidate enzymes, researchers can delineate the roles of specific proteolytic pathways in modulating natriuretic peptide availability and function. Such studies contribute to the broader understanding of peptide turnover and regulation in physiological processes.

Peptide synthesis and method development: The analog is also utilized as a reference standard and model substrate in the optimization of solid-phase peptide synthesis protocols and analytical method validation. Its defined sequence and physicochemical properties make it suitable for calibrating chromatographic systems, evaluating purification strategies, and benchmarking analytical techniques such as mass spectrometry and HPLC. These applications support the advancement of peptide chemistry and quality control in both research and industrial settings.

1. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

2. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

3. The spatiotemporal control of signalling and trafficking of the GLP-1R

4. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

5. Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells